Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Subcommittee at the Rayburn House Office Building on May 15, 2024 in Washington, DC. Kevin Dietsch | Getty Images News | Getty Images The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the…
Read More “FTC sues drug middlemen for allegedly inflating insulin prices” »
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this…
Read More “Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock” »
Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug…
Read More “Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says” »
Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, lower on Friday. Eli Lilly shares dropped…
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re…
Read More “In this fast-paced bull market, we’re increasing our Club price targets on 4 stocks” »
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. …
Read More “The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead” »
Game-changing anti-obesity medications have posed nothing short of an existential crisis for Weight Watchers parent WW International since they arrived on the scene, but CEO Sima Sistani has been confronting this challenge head-on. Despite an 11% dive in the stock Friday, Morgan Stanley said it thinks the company “has gone through an incredible transformation over…
Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. It wasn’t the first rout in the sector — the pressure has persisted for several months. The fear has been that whenever you have a large group of consumers changing…
